Antiplatelet Therapy for Percutaneous Coronary Intervention: Something Old and Something New
| Autor: | Michael A. Gaglia |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Pharmacology
medicine.medical_specialty Prasugrel business.industry medicine.medical_treatment Percutaneous coronary intervention 030204 cardiovascular system & hematology Clopidogrel Clinical trial 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine P2Y12 Cangrelor chemistry Internal medicine Cardiology Medicine Platelet aggregation inhibitor Pharmacology (medical) 030212 general & internal medicine business Intensive care medicine Ticagrelor medicine.drug |
| Zdroj: | Current Cardiovascular Risk Reports. 11 |
| ISSN: | 1932-9563 1932-9520 |
| DOI: | 10.1007/s12170-017-0533-x |
| Popis: | Antiplatelet therapy for patients undergoing percutaneous coronary intervention has rapidly evolved over the last 10 years, often outpacing clinical guidelines. This review appraises recent clinical trials within the context of landmark trials in interventional cardiology, and offers a framework for the integration of recent trials into clinical practice. This review interprets recent evidence regarding the following: (1) aspirin and the most effective dose; (2) the role of the newer, more potent P2Y12 inhibitors prasugrel, ticagrelor, and cangrelor; (3) an appraisal of the evolving paradigm for duration of dual antiplatelet therapy; and (4) perspective on the role of glycoprotein IIb/IIIa inhibitors in the era of routine and potent P2Y12 inhibition. The newer and more potent P2Y12 inhibitors, as well as a more nuanced understanding of mainstays of treatment like aspirin, offer the promise of maximizing ischemic benefit and minimizing bleeding in patients undergoing percutaneous coronary intervention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink